A 17-Gene Panel Genomic Prostate Score Has Similar Predictive Accuracy for Adverse Pathology at Radical Prostatectomy in African American and European American Men



      To validate the 17-gene Oncotype DX Genomic Prostate Score (GPS) as a predictor of adverse pathology (AP) in African American (AA) men and to assess the distribution of GPS in AA and European American (EA) men with localized prostate cancer.


      The study populations were derived from 2 multi-institutional observational studies. Between February 2009 and September 2014, AA and EA men who elected immediate radical prostatectomy after a ≥10-core transrectal ultrasound biopsy were included in the study. Logistic regressions, area under the receiver operating characteristics curves (AUC), calibration curves, and predictive values were used to compare the accuracy of GPS. AP was defined as primary Gleason grade 4, presence of any Gleason pattern 5, and/or non-organ-confined disease (≥pT3aN0M0) at radical prostatectomy.


      Overall, 96 AA and 76 EA men were selected and 46 (26.7%) had AP. GPS result was a significant predictor of AP (odds ratio per 20 GPS units [OR/20 units] in AA: 4.58; 95% confidence interval (CI) 1.8-11.5, P = .001; and EA: 4.88; 95% CI 1.8-13.5, P = .002). On multivariate analysis, there was no significant interaction between GPS and race (P >.10). GPS remained significant in models adjusted for either National Comprehensive Cancer Network (NCCN) risk group or Cancer of the Prostate Risk Assessment (CAPRA) score. In race-stratified models, area under the receiver operating characteristics curves for GPS/20 units was 0.69 for AAs vs 0.74 for EAs (P = .79). The GPS distributions were not statistically different by race (all P >.05).


      In this clinical validation study, the Oncotype DX GPS is an independent predictor of AP at prostatectomy in AA and EA men with similar predictive accuracy and distributions.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Brawley OW.
        Trends in prostate cancer in the United States.
        J Natl Cancer Inst Monogr. 2012; 2012: 152-156
        • Klotz L
        • Vesprini D
        • Sethukavalan P
        • et al.
        Long-term follow-up of a large active surveillance cohort of patients with prostate cancer.
        J Clin Oncol. 2014; 33: 272-277
        • Bangma C
        • Roemeling S
        • Schröder F
        Overdiagnosis and overtreatment of early detected prostate cancer.
        World J Urol. 2007; 25: 3-9
        • Klein EA
        • Maddala T
        • Millward C
        • et al.
        Development of a needle biopsy-based genomic test to improve discrimination of clinically aggressive from indolent prostate cancer.
        Am Soc Clin Oncol. 2012;
        • Loeb S
        • Tosoian JJ.
        Biomarkers in active surveillance.
        Transl Androl Urol. 2018; 7: 155
        • Knezevic D
        • Goddard AD
        • Natraj N
        • et al.
        Analytical validation of the Onco type DX prostate cancer assay–a clinical RT-PCR assay optimized for prostate needle biopsies.
        BMC Genomics. 2013; 14: 690
        • Cooperberg M
        • Simko J
        • Falzarano S
        • et al.
        Development and validation of the biopsy-based genomic prostate score (GPS) as a predictor of high grade or extracapsular prostate cancer to improve patient selection for active surveillance.
        J Urol. 2013;
        • Cullen J
        • Rosner IL
        • Brand TC
        • et al.
        A biopsy-based 17-gene genomic prostate score predicts recurrence after radical prostatectomy and adverse surgical pathology in a racially diverse population of men with clinically low-and intermediate-risk prostate cancer.
        Euro Urol. 2015; 68: 123-131
        • Sundi D
        • Ross AE
        • Humphreys EB
        • et al.
        African American men with very low–risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them?.
        J Clin Oncol. 2013; 31: 2991
        • Chornokur G
        • Dalton K
        • Borysova ME
        • Kumar NB
        Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer.
        Prostate. 2011; 71: 985-997
        • Vijayakumar S
        • Henegan JC
        • Zhang X
        • et al.
        Enriching gene expression profiles will help personalize prostate cancer management for African-Americans: a perspective.
        in: Paper presented at: urologic oncology: seminars and original investigations. 2017
        • Powell IJ
        • Dyson G
        • Land S
        • et al.
        Genes associated with prostate cancer are differentially expressed in African American and European American men.
        Cancer Epidemiol Prev Biomarkers. 2013; 22: 891-897
        • Kinseth MA
        • Jia Z
        • Rahmatpanah F
        • et al.
        Expression differences between African American and Caucasian prostate cancer tissue reveals that stroma is the site of aggressive changes.
        Int J Cancer. 2014; 134: 81-91
        • Faisal FA
        • Sundi D
        • Tosoian JJ
        • et al.
        Racial variations in prostate cancer molecular subtypes and androgen receptor signaling reflect anatomic tumor location.
        Euro Urol. 2016; 70: 14-17
        • Epstein JI
        • Egevad L
        • Amin MB
        • Delahunt B
        • Srigley JR
        • Humphrey PA
        The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma.
        Am J Surg Pathol. 2016; 40: 244-252
        • Carroll PH
        • Mohler JL
        NCCN Guidelines Updates: Prostate Cancer and Prostate Cancer Early Detection.
        J Natl Compr Canc Netw. 2018; 16: 620-623
        • Pencina MJ
        • D'Agostino Sr RB
        • D'Agostino Jr, RB
        • Vasan RS
        Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond.
        Stat Med. 2008; 27: 157-172
        • Cooperberg MR
        • Pasta DJ
        • Elkin EP
        • et al.
        The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy.
        J Urol. 2005; 173: 1938-1942
      1. Memorial Sloan Kettering Cancer Center: Prediction tools/prostate cancer nomograms: PreRadical prostatectomy. Available at: Accessed November 22, 2019.

        • Butler S
        • Muralidhar V
        • Chavez J
        • et al.
        Active surveillance for low-risk prostate cancer in black patients.
        New Eng J Med. 2019; 380: 2070
        • Bloom JB
        • Lebastchi AH
        • Gold SA
        • et al.
        Use of multiparmetric MRI and fusion‐guided biopsies to properly select and follow African‐American men on active surveillance.
        BJU Int. 2019;
        • Davis JW.
        Novel commercially available genomic tests for prostate cancer: a roadmap to understanding their clinical impact.
        BJU Int. 2014; 114: 320-322
        • Klein EA
        • Cooperberg MR
        • Magi-Galluzzi C
        • et al.
        A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.
        Euro Urol. 2014; 66: 550-560
        • Badani KK
        • Kemeter MJ
        • Febbo PG
        • et al.
        The impact of a biopsy based 17-gene genomic prostate score on treatment recommendations in men with newly diagnosed clinically prostate cancer who are candidates for active surveillance.
        Urol Pract. 2015; 2: 181-189
        • Eure G
        • Germany R
        • Given R
        • et al.
        Use of a 17-gene prognostic assay in contemporary urologic practice: results of an interim analysis in an observational cohort.
        Urology. 2017; 107: 67-75
        • Iremashvili V
        • Soloway MS
        • Rosenberg DL
        • Manoharan M
        Clinicaland demographic characteristics associated with prostate cancer progression in patients on active surveillance.
        J Urol. 2012; 187: 1594-1600
        • Shao Y-H
        • Demissie K
        • Shih W
        • et al.
        Contemporary risk profile of prostate cancer in the United States.
        J Nat Cancer Ins. 2009; 101: 1280-1283
        • Sanchez‐Ortiz RF
        • Troncoso P
        • Babaian RJ
        • Lloreta J
        • Johnston DA
        • Pettaway CA
        African‐American men with nonpalpable prostate cancer exhibit greater tumor volume than matched white men.
        Cancer. 2006; 107: 75-82
        • Powell IJ
        • Bock CH
        • Ruterbusch JJ
        • Sakr W
        Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity.
        J Urol. 2010; 183: 1792-1797
        • Rosen P
        • Pfister D
        • Young D
        • et al.
        Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer.
        Urology. 2012; 80: 749-753
        • Farrell J
        • Petrovics G
        • McLeod D
        • Srivastava S
        Genetic and molecular differences in prostate carcinogenesis between African American and Caucasian American men.
        Int J Mol Sci. 2013; 14: 15510-15531